BJDX
Bluejay Diagnostics, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.94
+11.48%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.86
From 52W high−93.27%
Volume839866.00
Market cap$4.21M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.86
From 52W high
−93.27%
Volume
839866.00
Market cap
$4.21M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.7x
P/E (TTM)
—
RSI (14)
48.1
MomentumView details →
1D Return
+11.48%
YTD Return
−64.79%
SummaryUpdated Jun 1, 2026
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) is a medical device company founded in 2015 and headquartered in Acton, Massachusetts. The company went public in November 2021 and focuses on developing point-of-care diagnostic solutions for healthcare providers. Bluejay operates in the early-stage medical diagnostics sector, developing innovative testing platforms designed to improve patient care through rapid, accurate diagnostic capabilities at the point of care.
Similar companies
Latest newsMore news →
Bluejay Diagnostics and Lovell Government Services announced a partnership to expand access to U.S. federal healthcare markets, establishing a federal distribution and co-marketing framework across VA, DoD, Military Health Systems and other government healthcare channels.12d agoBluejay Diagnostics, Inc. elected Donald Chase, Neil Dey, Svetlana Dey, Douglas Wurth, and Fred Zeidman as directors, effective June 9, 2026.103d ago